Compare Crispr Therapeutics AG (CRSP) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs JPMorgan Chase & Co — how do they compare? Crispr Therapeutics AG trades at $51.28 (market cap $4.97B), while JPMorgan Chase & Co trades at $347.74 (market cap $911.47B). The key difference: JPMorgan Chase & Co is far larger — about 183.4× Crispr Therapeutics AG's market cap, and JPMorgan Chase & Co pays a 1.75% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | JPM | |
|---|---|---|
Market Cap | $4.97B | $911.47B |
Sector | Health | Financials |
52-Week High | $76.78 | $342.89 |
52-Week Low | $44.34 | $282.84 |
Enterprise Value | $3.32B | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
JPMorgan Chase (JPM) trades at $342.89, up 2.5% on the day, with a bullish technical outlook and strong analyst support. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth from $181.85B in 2025 to $186.4B projected for 2026. The stock shows robust fundamentals with a P/E of 14.69 and ROE of 17.03%, though cash flow trends indicate volatility.
The outlook is positive with a consensus price target of $377.75, offering ~10% upside. Risks include geopolitical tensions and cybersecurity threats, but institutional buying and CEO Dimon's leadership provide stability. Investors should weigh earnings consistency against macroeconomic uncertainties for potential gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
